US 12,258,387 B2
Anti-BAG3 antibodies as therapeutic reagent in cardiovascular disease
Maria Caterina Turco, Avellino (IT); Liberato Marzullo, Scalea (IT); Alessandra Rosati, Baronissi (IT); Margot De Marco, Salerno (IT); and Anna Basile, Bracigliano (IT)
Assigned to FIBROSYS S.R.L., Baronissi (IT)
Filed by FIBROSYS S.R.L., Baronissi (IT)
Filed on Mar. 24, 2022, as Appl. No. 17/703,747.
Application 17/703,747 is a division of application No. 17/040,468, abandoned, previously published as PCT/EP2018/070259, filed on Jul. 26, 2018.
Claims priority of application No. 102017000087307 (IT), filed on Jul. 28, 2017; and application No. 102017000113648 (IT), filed on Oct. 10, 2017.
Prior Publication US 2022/0213182 A1, Jul. 7, 2022
Int. Cl. A61K 39/395 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/3955 (2013.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01)] 8 Claims
 
1. A method for treating a cardiovascular disease in a patient, comprising the step of administering a pharmaceutical composition consisting essentially of an anti-BAG3 antibody to a patient in need thereof, where the cardiovascular disease is selected from the group consisting of: angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure, and iatrogenic heart disease,
wherein the anti-BAG3 antibody is:
(i) a humanized antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 12, 14, 16, or 18, and a light chain comprising the amino acid sequence of SEQ ID NO: 20, 22, 24, or 26; or
(ii) a humanized antibody comprising a heavy chain comprising H-CDR1 having the amino acid sequence of SEQ ID NO: 5, H-CDR2 having the amino acid sequence of SEQ ID NO: 6, and H-CDR3 having the amino acid sequence of SEQ ID NO: 7, and a light chain comprising L-CDR1 having the amino acid sequence of SEQ ID NO: 8, L-CDR2 having the amino acid sequence of SEQ ID NO: 9, and L-CDR3 having the amino acid sequence of SEQ ID NO: 10.